Expert Interview
Comparing Neurocrine Biosciences pediatric study results of Crinecerfont in Children and Adolescents with Spruce Biosciences Tildacerfont CAHptain-205 study and dose finding presentation at the Pediatric Endocrine Society (PES) 2024
Ticker(s): SPRB, NBIXInstitution: OHSU
- Professor and Chair (emeritus) of Pediatrics, Oregon Health & Science University
- Has treated patients with achondroplasia for 40 years, currently involved in treatment decisions for 6 patients.
- Internationally renowned authority on the endocrine basis of growth and development and has been at the forefront of understanding the biology of growth hormone (GH) and growth factors for over 30 years.
How did the crinecerfont pediatric study patient population baselines compare with tildacerfont's CAHptain study?
Added By: gpcphoenixWhat is the range in pediatric congenital adrenal hyperplasia (CAH) patient disease characteristics compared to adult population?
Added By: gpcphoenixCan crincerfont or tildacerfont pediatric intervention theoretically stop disease progression as patients reach adulthood?
Added By: gpcphoenixAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
